stock rating
Evercore Initiates Quest Diagnostics With In-Line Rating
Evercore's Elizabeth Anderson said the bank sees favorable conditions for Quest's base business but believes a recent stock run-up has priced much of that in.
Cowen Upgrades PerkinElmer Stock to Outperform
Analyst Max Masucci said the firm is expected to generate at least $3.21 billion in COVID-19-related revenues, while he lowered the stock price target to $164 per share.
Hologic Upgraded to Outperform by Evercore ISI
Investors are refocusing on Hologic's base business given an anticipated major cut to COVID-19 industry testing revenues in fiscal year 2022, according to Evercore.
Piper Sandler Raises Rating on Oncocyte to Overweight
The rating increase follows Oncocyte's Chinese distribution deal for its DetermaRx lung cancer treatment stratification test with Burning Rock Biotech.
JP Morgan Downgrades Illumina to Neutral on Grail Deal
Along with the downgrade, the investment bank also lowered its December 2021 price target for Illumina from $390 to $280.